Celgene Corporation

Celgene Quanticel Research, Inc.

Paula Alessandra Tavares-Greco

Hon-Wah Man

Gerald D Artman, Iii

Jeffrey Alan Stafford

James Marvin Veal

Toufike Kanouni

Stephen W Kaldor

Young K Chen

Matthew David Alexander

Joshua Hansen

Matthew Daniel Correa

Mark A Nagy

Brandon Wade Whitefield

Matthew Michael Kreilein

Nanfei Zou

Xiaoling Lu

Antonia Lopez-Girona

Timothy S Kercher

Brian Edwin Cathers

Daniel W Pierce

Lilly L Wong

Courtney G Havens

James Carmichael

Joseph R Piccotti

Lianfeng Huang

Rama Krishna Narla

Antonio Christian Ferretti

Wenju Wu

Soraya Carrancio

Nancy Tsou

Udaykumar Jain

Zhiwei Yin

Gordon L Bray

Antonio C Ferretti

Iii Gerald D Artman

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

Antiproliferative compounds and methods of use thereof

Provided herein are formulations, processes, solid forms and methods of use relating to salts of and solid forms comprising free base or salts of (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile.

Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same

Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.

Compositions comprising an inhibitor of lysine specific demethylase-1

Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.

Growing community of inventors

Parsippany, NJ, United States of America

Paula Alessandra Tavares-Greco